Earnings Outlook: All eyes will be on Gilead’s hepatitis C franchise as it reports fourth-quarter earnings

Gilead Sciences Inc. first became notorious in 2014 for the high price of its hepatitis C drug Sovaldi: More than $80,000 for a course of treatment.

The company’s hepatitis C franchise will again be in the spotlight, this time for flagging sales, when Gilead GILD, +0.07% reports fourth-quarter earnings, scheduled for Tuesday after the markets close.

Both Sovaldi and sister product Harvoni cure hepatitis C, which Gilead has used as a rationale for their high price tags.

But it’s also become a more enduring problem, with the company struggling to get enough new prescriptions to sustain and grow its sales numbers.

>>> Original Source <<<